Episodes

  • Zepbound Explained — The New Weight Loss Drug - The Numbers Don't Lie

    Zepbound Explained — The New Weight Loss Drug - The Numbers Don't Lie
    Apr 7 2026
    Join AI host Julia Cartwright as she breaks down the groundbreaking SURMOUNT clinical trials for tirzepatide (Zepbound). We cover the landmark data showing average weight loss of 21% at the highest dose, with 57% of participants losing over 20% of body weight—results previously seen only with bariatric surgery, fundamentally reshaping obesity medicine's possibilities.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Show More Show Less
    23 mins
  • Zepbound Explained — The New Weight Loss Drug - Who Gets the Shot? Eligibility & Access

    Zepbound Explained — The New Weight Loss Drug - Who Gets the Shot? Eligibility & Access
    Apr 7 2026
    Julia Cartwright explores who qualifies for Zepbound, the GLP-1 weight loss medication showing 15-21% body weight reduction in trials. Learn FDA eligibility criteria, BMI thresholds, required comorbidities, and how to navigate the complex insurance prior authorization process that stands between patients and this transformative treatment option.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Show More Show Less
    22 mins
  • Zepbound Explained — The New Weight Loss Drug - The Twincretin: One Shot, Two Hormones

    Zepbound Explained — The New Weight Loss Drug - The Twincretin: One Shot, Two Hormones
    Apr 7 2026
    Julia Cartwright breaks down the science behind Zepbound (tirzepatide), the FDA-approved weight loss drug that targets two gut hormones simultaneously. Learn how this once-weekly injection helped clinical trial participants lose up to 21% of their body weight by suppressing appetite, delaying digestion, and regulating metabolism—without gimmicks, just biochemistry.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Show More Show Less
    24 mins